Regulation
Cannabis Rescheduling Advances: Schedule III Is Within Reach
The cannabis rescheduling process advances significantly in 2024 as the DEA moves forward with the proposed rule to move cannabis to Schedule III.
Closer Than Ever
2024 is proving to be the year cannabis rescheduling finally becomes reality. The DEA has published its proposed rule to move cannabis from Schedule I to Schedule III, initiating a public comment period that brings the industry one step closer to historic reform.
The Proposed Rule
Key elements of the DEA's proposal:
- Reclassification from Schedule I to Schedule III
- Acknowledgment of cannabis's accepted medical use
- Lower abuse potential classification
- Maintained regulation — not full deregulation
- State programs continue to operate
Impact of Schedule III
Tax Relief
- 280E eliminated — cannabis businesses can deduct normal expenses
- Estimated savings of $1.8 billion annually for the industry
- Increased profitability enabling growth and investment
Banking
- Reduced compliance burden for financial institutions
- More banks willing to serve cannabis businesses
- Credit card processing becoming more feasible
- Investment capital flowing more freely
Research
- Simplified licensing for cannabis research
- More institutions able to conduct studies
- FDA pathway for cannabis-based pharmaceuticals
- Data generation supporting medical claims
What Hasn't Changed
Important to note what rescheduling does not do:
- Does not legalize recreational cannabis federally
- Does not preempt state laws
- Does not create a federal recreational framework
- Does not immediately resolve all banking issues
Budbo's Response
Rescheduling creates enormous tailwinds for the Budbo platform:
- Healthier operators with better margins invest more in technology
- Banking access enables digital payments
- Research data improves product recommendations
- Institutional interest grows in cannabis technology
The Path Forward
The public comment period will conclude, and the DEA will issue a final rule. While the exact timeline is uncertain, the direction is clear: Schedule III is coming, and it will transform the cannabis industry.
Budbo is building for that transformed industry.
- rescheduling
- Schedule III
- DEA
- 280E
- federal policy
From the Budbo archive. Details about products, prices and laws reflect the time of writing.